CN | EN
 SHOWNBIO
"continuous innovation, pursuit of excellence, focus on molecular specificity analysis, to protect the research and development of new drugs."
PLATFORM INTRODUCTION
Membrance Protein Array
The membrane protein array technology is to express plasma membrane proteins in a natural state directly in cells , keeping their structural integrity and natural post-translational modification, and on this basis, to form a cell array, which is used to identify the targeting specificity of antibodies, drugs or other ligands that bind to membrane proteins, and to provide a comprehensive cross-reaction assessment for the new regulatory requirements of IND declaration of CAR-T, antibodies and other drugs. At the same time, this technique can also be used in many fields, such as new target discovery, virus mechanism analysis, ligand-receptor de-orphaning .
SERVICE APPLICATION
  • Safety evaluation of new drugs
    Drug off-target is a key parameter to evaluate drug safety, which will lead to unpredictable clinical toxicity and affect the development of clinical trials ...
  • New target discovery
    Taking CAR-T target research as an example, the current target in clinical research is mainly focused on CD19. The proportion of CAR-T clinical trials targeting CD19 in China ...
  • Virus mechanism study
    The process of virus invading host cells can be divided into six steps: adsorption, invasion, shelling, synthesis, assembly and release.Adsorption is not only the key to...
  • Ligand-Receptocr de-orphaning
    Orphan receptor are receptors that are structurally similar to other identified receptors, but whose endogenous ligands have not yet been discovered.
CASE
  • Specificity analysis of monoclonal antibody
    In recent years, monoclonal antibody drugs, including antibody coupling drugs, have been widely used in the treatment of various diseases, but it is not uncommon for serious clinical side effects to occur due to mistargeting. In the process of antibody drug development, the closer the candidate molecules are to the terminal detection, the higher the cost of development failure.
  • ScFvs specificity analysis
    As a "live medicine" different from traditional medicine, CAR-T therapy brings breakthrough surprises to the market in the field of tumor therapy. ScFv is one of the most critical components of CAR-T drugs, and its specificity determines the safety of CAR-T therapy.
FREQUENTLY ASKED QUESTION
  • Which molecules can be detected by MPA technology?

     MPA technology can screen a wide range of testing objects, including IgG, ScFv, ADC, VHH, CAR molecules (detecting the extracellular segment of CAR), viruses, small molecules, peptides and so on.


  • Which protein tags or tags are compatible with the platform?

    We have considerable experience in a variety of detection strategies, including biotin-streptavidin, Fc, His, HA, Flag or other markers, but we prefer biotin-labeled samples.


  • What materials will be received after the completion of the project?

    A detailed targeting confirmation report will be received, including preliminary experimental parameters, quality control parameters, antibody concentration parameters, high-throughput screening and final targeting confirmation.


  • How many sample material is required?

    Our recommended sample delivery volume is at least 2mg, During the construction of our previous system, it was proved that this sample delivery can meet the MPA test of 90% of the sample.



  • What kind of sample information does the customer need to provide?

    Sample name, sample concentration, dissolved Buffer, sample label, Fc subtype, positive control antigen name, as well as affinity data or flow binding data, sample purity information, etc.


  • How long is the data archived?

    All data generated during the test shall be uniformly filed and preserved by the quality Management Committee, and the test scheme and report, the original and electronic versions of the key records will be kept permanently, and other non-critical auxiliary records will be kept at least 5 years after the relevant products are approved for listing.


PARTNERS
  • 30+
    Cooperative customers
  • 100+
    Cases
  • 3+
    IND Cases
ABOUT US
ShownBio is a leading biotechnology company specializing in antibody specificity analysis . Since the company was founded in 2019, ShownBio independently constructed 6000+ plasma membrane proteins , established an automated, high-throughput detection platform, created a data visualization, traceable quality system, and created an internationally leading protein specific verification platform, which can provide "one-stop, integrated" protein non-specific screening services. The specificity verification platform includes 5 functional modules and 5 platforms, which provide systematic solutions for drug safety evaluation, provide theoretical basis for the study of virus mechanism, and provide scientific research ideas for ligand receptor orphaning. Provide design support for drug development and provide new possibilities for target discovery.